Ubs Oconnor LLC Arvinas, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 20,000 shares of ARVN stock, worth $502,200. This represents 0.03% of its overall portfolio holdings.

Number of Shares

20,000

Holding current value

$502,200

% of portfolio

0.03%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$23.66 - $32.73 $68,566 - $94,851	-2,898 Reduced 9.56%	27,403 $674,000
Q2 2024 Aug 14, 2024	SELL	$24.46 - $40.4 $29,352 - $48,480	-1,200 Reduced 3.81%	30,301 $806,000
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $2.17 Million - $3.12 Million	-59,631 Reduced 65.43%	31,501 $1.3 Million
Q4 2023 Feb 14, 2024	SELL	$14.19 - $42.33 $270,319 - $806,386	-19,050 Reduced 17.29%	91,132 $3.75 Million
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $333,880 - $479,570	17,000 Added 18.24%	110,182 $2.16 Million
Q2 2023 Aug 14, 2023	BUY	$21.73 - $31.43 $2.02 Million - $2.93 Million	93,182 New	93,182 $2.31 Billion
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $924,402 - $1.32 Million	35,350 New	35,350 $965,000

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

Vanguard Group Inc Valley Forge, PA

7.01M
Shares

$176 Million
0.0% of portfolio
Eco R1 Capital, LLC San Francisco, CA

6.73M
Shares

$169 Million
7.19% of portfolio
Black Rock Inc. New York, NY

6.26M
Shares

$157 Million
0.0% of portfolio
Price T Rowe Associates Inc Baltimore, MD

3.85M
Shares

$96.8 Million
0.01% of portfolio
Rtw Investments, LP New York, NY

2.78M
Shares

$69.9 Million
1.09% of portfolio

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.34B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account